The biotech company biocrates life sciences, based in Innsbruck, Austria, creates the conditions for evidence-based metabolic analysis with standardised technology. The analysis of metabolic products (metabolomics) in addition to genetic and other conventional parameters enables scientists to detect changes in metabolism at an early stage and to draw conclusions about future developments that can be influenced.

biocrates on the collaboration with MIG:

“MIG Capital AG has enabled biocrates to become synonymous with scientifically sound metabolic analysis. The regular exchange with the experienced team challenges us and provides us with additional perspectives. Together, we are working with foresight to create the foundations for a new and sustainable medical approach with metabolomics.” Moritz Seuster, CEO